Islam Elkonaissi, The Royal Marsden NHS Foundation Trust, London, UK, outlines the risk of developing hyperglycemia through steroid treatment in patients with non-small cell lung cancer treatment (NSCLC) who are receiving immunotherapy, and explains how we might minimize this risk. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.